63 completed, 3 terminated, 2 withdrawn, 1 suspended. 26 Phase 3, 14 Phase 1, 9 Phase 4, 8 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 26 | Completed 26 |
| Phase 1 | 14 | Completed 13, Terminated 1 |
| Phase 4 | 9 | Completed 6, Terminated 2, Withdrawn 1 |
| Phase 2 | 8 | Completed 7, Withdrawn 1 |
| Not applicable | 1 | Suspended 1 |
Follow olodaterol: new trials by email Literature Review of olodaterol trials Research Report on olodaterol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD Tiotropium, Olodaterol, Umeclidinium - COPD (Chronic Obstructive Pulmonary Disease) | Not applicable | Suspended | Medical University of Bialystok | 100 | 2024-03-11 | 2026-10-02 |
| ANTES B+ Clinical Trial Trelegy Ellipta 100/62.5/25Mcg Inh 30D, Brimica, Duaklir - Chronic Obstructive Pulmonary Disease | Phase 4 | Terminated | Fundacio Privada Mon Clinic Barcelona | 48 | 2024-02-29 | 2025-08-14 |
| Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan Tiotropium (Tio), Inhaled corticosteroids (ICS), Olodaterol (Olo) - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 17018 | 2022-09-30 | 2024-08-09 | |
| A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD) Trelegy Ellipta, Stiolto Respimat, Tiotropium + Olodaterol (5/5 mcg) - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 9117 | 2021-12-17 | 2023-10-19 | |
| Effects of Acute Long-acting Bronchodilation on Oxygenation and Peripheral Ventilation in COPD LABA, LAMA - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Erasme University Hospital | 30 | 2021-06-15 | 2023-07-03 |
| A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol Trelegy Ellipta, Stiolto Respimat, Furoate/Umeclidinium/Vilanterol - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 11316 | 2021-02-26 | 2023-11-13 | |
| Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece Tiotropium bromide plus Olodaterol - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 1396 | 2021-02-16 | 2024-06-25 | |
| Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study Tiotropium bromide + Olodaterol, Sp(t)iolto® Respimat® - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 1371146 | 2019-11-15 | 2021-11-15 | |
| Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS Tiotropium bromide + Olodaterol, LABA/ICS - COPD | Completed | Boehringer Ingelheim | 42953 | 2019-11-01 | 2021-11-15 | |
| Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy Tiotropium and Olodaterol (Tio+Olo), Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS) - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 27190 | 2019-11-01 | 2021-11-15 | |
| Re-usable Respimat® Soft MistTM Inhaler Study Respimat - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 262 | 2019-09-30 | 2021-03-03 | |
| A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD) Olodaterol/Tiotropium Bromide, Umeclidinium/ Vilanterol - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 11296 | 2019-06-10 | 2021-11-15 | |
| Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease Bronchodilator Agents - Pulmonary Disease, Chronic Obstructive | Phase 4 | Terminated | Università degli Studi di Ferrara | 843 | 2018-11-11 | 2022-12-28 |
| Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD RPL554 Suspension, Placebo, Tiotropium/olodaterol (Respimat) - COPD | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 79 | 2018-07-16 | 2019-10-10 |
| The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus Tiotropium, Olodaterol, Fluticasone propionate - Pulmonary Disease, Chronic Obstructive | Phase 4 | Completed | Boehringer Ingelheim | 302 | 2017-08-14 | 2020-04-16 |
| Cardiovascular Function in COPD Patients Tiotropium, Olodaterol, Fluticasone propionate - Pulmonary Disease, Chronic Obstructive | Phase 4 | Completed | Boehringer Ingelheim | 76 | 2017-03-29 | 2019-08-16 |
| The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease Stiolto Respimat, Placebo Respimat - Chronic Obstructive Pulmonary Disease | Phase 4 | Completed | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 14 | 2017-03-01 | 2020-08-06 |
| Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients Tiotropium, Olodaterol - Pulmonary Disease, Chronic Obstructive | Phase 1 | Completed | Boehringer Ingelheim | 12 | 2017-02-24 | 2019-03-29 |
| Drug Utilization Study for Olodaterol Olodaterol, Indacaterol - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 27606 | 2017-02-08 | 2019-06-27 | |
| Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination) - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 3223 | 2016-12-19 | 2022-03-28 |
Showing 20 of 69. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (55) · Asthma (5)
Boehringer Ingelheim (61) · Erasme University Hospital (1) · Fundacio Privada Mon Clinic Barcelona (1) · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (1) · Medical University of Bialystok (1) · RWTH Aachen University (1) · University of Dundee (1) · Università degli Studi di Ferrara (1) · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (1)
Germany (29) · United States (27) · Canada (18) · Belgium (13) · Denmark (12) · Netherlands (11) · Austria (10) · Finland (8) · France (8) · Spain (8) · Sweden (8) · Argentina (7) · Australia (7) · Hungary (7) · Italy (7)
Brian Lipworth, MD, Mb Chb (1) · Dave Singh (1) · Harry Rossiter, PhD (1) · Maria Katsamani, +30 210 8906 108 (1) · Michael Dreher, MD (1) · Richard Casaburi, PhD, MD (1) · Robert M Mroz, professor (1) · Sunny Jabbal, Mb Chb (1)
PMID 32943047, PMID 30077810, PMID 32462607, PMID 32671684, PMID 32848381, PMID 30261995, PMID 32776202, PMID 24966672, PMID 25045258, PMID 25187881, PMID 25342898, PMID 25573406, PMID 26112656, PMID 26283085, PMID 26320402, PMID 27316465, PMID 27383762, PMID 27993292, PMID 28424359, PMID 29355547, PMID 32848379, PMID 32848380, PMID 33175291, PMID 20956145, PMID 23155808, PMID 25776199, PMID 25956072, PMID 26404912, PMID 27044576, PMID 27075841, PMID 29439648, PMID 29605624, PMID 31496678, PMID 32349720, PMID 32916296, PMID 33180376, PMID 33548471, PMID 33721209, PMID 35323052, PMID 37133429, PMID 39968202
2009 (8), 2008 (4), 2015 (3), 2014 (2), 2023 (1)